const e=[{drugs:["aspirin","warfarin"],severity:"major",mechanism:"Additive anticoagulant/antiplatelet effects",effect:"Significantly increased bleeding risk",management:"Avoid combination or monitor very closely; frequent INR checks",evidence_level:"A",sources:["Clinical literature","FDA guidelines"]},{drugs:["oxycodone","ketoconazole"],severity:"major",mechanism:"CYP3A4 inhibition increases oxycodone exposure",effect:"Enhanced sedation and respiratory depression",management:"Avoid or reduce oxycodone dose; monitor closely",evidence_level:"B",sources:["FDA"]},{drugs:["fentanyl","clarithromycin"],severity:"major",mechanism:"CYP3A4 inhibition increases fentanyl levels",effect:"Risk of fatal respiratory depression",management:"Avoid combination; consider alternative antibiotic",evidence_level:"A",sources:["FDA"]},{drugs:["methadone","amiodarone"],severity:"major",mechanism:"Additive QT prolongation",effect:"Torsades de pointes risk",management:"Avoid combination; ECG monitoring if unavoidable",evidence_level:"B",sources:["Cardiology guidelines"]},{drugs:["warfarin","ciprofloxacin"],severity:"moderate",mechanism:"CYP1A2/3A4 inhibition increases warfarin exposure",effect:"Increased INR and bleeding risk",management:"Monitor INR closely; adjust warfarin dose if needed",evidence_level:"B",sources:["Clinical studies"]},{drugs:["digoxin","amiodarone"],severity:"major",mechanism:"P-glycoprotein inhibition increases digoxin levels",effect:"Digoxin toxicity risk",management:"Reduce digoxin dose by 50%; monitor levels closely",evidence_level:"A",sources:["Cardiovascular pharmacology"]},{drugs:["theophylline","ciprofloxacin"],severity:"major",mechanism:"CYP1A2 inhibition reduces theophylline clearance",effect:"Theophylline toxicity with seizures possible",management:"Avoid combination or reduce theophylline dose significantly",evidence_level:"A",sources:["FDA","Clinical studies"]},{drugs:["simvastatin","gemfibrozil"],severity:"major",mechanism:"Inhibition of simvastatin glucuronidation",effect:"Severe myopathy and rhabdomyolysis risk",management:"Avoid combination; use alternative statin if needed",evidence_level:"A",sources:["FDA warning"]},{drugs:["phenytoin","carbamazepine"],severity:"moderate",mechanism:"Mutual CYP3A4 induction",effect:"Reduced efficacy of both anticonvulsants",management:"Monitor seizure control; may need dose adjustments",evidence_level:"B",sources:["Neurology guidelines"]},{drugs:["lithium","hydrochlorothiazide"],severity:"major",mechanism:"Reduced lithium clearance",effect:"Lithium toxicity risk",management:"Monitor lithium levels frequently; adjust dose as needed",evidence_level:"A",sources:["Psychiatry guidelines"]},{drugs:["metformin","contrast media"],severity:"major",mechanism:"Risk of lactic acidosis with renal impairment",effect:"Potentially fatal lactic acidosis",management:"Hold metformin 48h before and after contrast administration",evidence_level:"A",sources:["Radiology guidelines","FDA"]},{drugs:["tacrolimus","fluconazole"],severity:"major",mechanism:"CYP3A4 inhibition increases tacrolimus exposure",effect:"Nephrotoxicity and immunosuppression",management:"Monitor tacrolimus levels; reduce dose significantly",evidence_level:"A",sources:["Transplant guidelines"]},{drugs:["clopidogrel","omeprazole"],severity:"moderate",mechanism:"CYP2C19 inhibition reduces clopidogrel activation",effect:"Reduced antiplatelet efficacy",management:"Use pantoprazole instead; avoid omeprazole/esomeprazole",evidence_level:"B",sources:["FDA","Cardiology societies"]},{drugs:["erlotinib","rifampin"],severity:"major",mechanism:"CYP3A4 induction reduces erlotinib exposure",effect:"Loss of therapeutic efficacy",management:"Avoid rifampin; use alternative anti-TB agent",evidence_level:"B",sources:["Oncology guidelines"]},{drugs:["imatinib","ketoconazole"],severity:"moderate",mechanism:"CYP3A4 inhibition increases imatinib exposure",effect:"Increased toxicity risk",management:"Consider imatinib dose reduction; monitor closely",evidence_level:"B",sources:["Oncology studies"]},{drugs:["pemetrexed","nsaids"],severity:"major",mechanism:"Reduced renal clearance of pemetrexed",effect:"Severe myelosuppression and mucositis",management:"Avoid NSAIDs 2 days before through 2 days after pemetrexed",evidence_level:"A",sources:["FDA label","Oncology guidelines"]},{drugs:["capecitabine","phenytoin"],severity:"moderate",mechanism:"Increased phenytoin levels via DPD inhibition",effect:"Phenytoin toxicity",management:"Monitor phenytoin levels; consider dose reduction",evidence_level:"B",sources:["Oncology literature"]},{drugs:["cyclophosphamide","allopurinol"],severity:"moderate",mechanism:"Enhanced bone marrow toxicity",effect:"Increased myelosuppression risk",management:"Monitor blood counts more frequently",evidence_level:"C",sources:["Oncology references"]},{drugs:["docetaxel","ketoconazole"],severity:"major",mechanism:"CYP3A4 inhibition increases docetaxel exposure",effect:"Severe neutropenia and toxicity",management:"Avoid strong CYP3A4 inhibitors during treatment",evidence_level:"B",sources:["FDA label"]},{drugs:["paclitaxel","carboplatin"],severity:"moderate",mechanism:"Sequence-dependent interaction",effect:"Enhanced myelosuppression if carboplatin given first",management:"Administer paclitaxel before carboplatin",evidence_level:"A",sources:["Clinical trials"]}];export{e as FALLBACK_INTERACTIONS,e as default};
